Spyre Therapeutics, Inc. Balance Sheet
SYRE / Health Care|12 years of annual SEC 10-K data (FY2014-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 12 fiscal years. All figures from audited SEC 10-K filings.
Spyre Therapeutics, Inc. had $778M in total assets and $715M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $85.7M | $89.4M | $188.9M | $34.9M | $15.1M | $90.1M | $19.3M | $22.5M | $12.8M | $47.7M | $29.3M | $2.6M |
| Current Assets | $777.8M | $608.5M | $341.5M | $62.3M | $98.9M | $149.8M | $74.5M | $76.7M | $55.0M | $66.4M | $38.3M | - |
| PP&E (Net) | - | - | $0 | $3.2M | $4.5M | $5.6M | $2.4M | $1.0M | $854.0K | $599.0K | $348.0K | - |
| Total Assets | $777.8M | $608.5M | $341.9M | $71.1M | $109.9M | $161.6M | $83.2M | $77.7M | $56.1M | $67.1M | $38.7M | - |
| Current Liabilities | $58.7M | $54.1M | $32.0M | $14.7M | $20.1M | $16.4M | $18.4M | $10.2M | $5.6M | $4.0M | $2.5M | - |
| Shareholders' Equity | $715.2M | $517.8M | $184.0M | $139.8M | $83.9M | $67.4M | $50.3M | $63.0M | $50.3M | $63.0M | -$22.2M | -$11.5M |